Transcatheter aortic valve implantation is a therapeutic alternative for high-surgical-risk patients with severe symptomatic aortic stenosis. Two models of prosthesis are currently commercialized in France, which can be implanted either via a transarterial or a transapical approach. The aim of the study was to evaluate in a national French registry the early safety and efficacy of transcatheter aortic valve replacement (AVR) using either the Edwards SAPIEN TM or CoreValve TM in high-surgical-risk patients with severe aortic stenosis.
Introduction
In 2002, the first transcatheter aortic valve implantation (TAVI) was performed by Cribier et al. 1 in a patient with severe aortic stenosis (AS) and cardiogenic shock. Seven years later, more than 8000 patients have been treated by TAVI worldwide using one of the two models of prosthesis now commercially available: the balloon expandable Edwards SAPIEN TM prosthesis (Edwards Lifesciences LLC, Irvine, CA, USA) and the self-expandable CoreValve TM (Medtronic CV, Irvine, CA, USA). Both of these were approved by the European Standards authorities in 2007, allowing their commercialization in Europe for the recommended indications.
Since the initial description of the transvenous, 2,3 transarterial 4 -7 , and transapical (TA) 8 -10 TAVI, the feasibility and safety of the TAVI technique have been confirmed and are rapidly gaining credibility as a viable alternative to open heart aortic valve replacement (AVR) in high-risk patients with severe AS. Dissemination from highly experienced centres to less experienced ones while maintaining similar results requires additional demonstration. The aim of our study was to evaluate TAVI in France in a large population of patients with severe degenerative symptomatic AS considered at too high risk or contra-indicated for conventional AVR, included in a multicentre prospective registry. This registry which reflects the real-life experience of selected centres in the country included patients treated with the two commercially available models utilizing both transarterial and TA approaches.
Methods

Study design and patient population
Between February and July 2009, a total of 244 consecutive patients were included in a prospective multicentre registry. This registry involved symptomatic adults requiring TAVI due to severe, degenerative, valvular AS, and who were very high-risk candidates for AVR surgery at the time of enrolment. The 16 centres which participated in the registry were selected by the French Ministry of Health based on: the presence of a multidisciplinary on-site team (interventional cardiologist, cardio-thoracic surgeon, anaesthetist, imaging specialist), annual volume of AVR (.200 patients/year), preliminary experience in balloon aortic valvuloplasty and/or TAVI and, finally, a homogeneous geographic distribution throughout the country. Ten centres were in their learning phase and the first procedures were supervised by a proctor. Three other centres had participated previously in the Edwards initial feasibility studies and three had started the TAVI program in 2008 with more than 10 cases performed. The two commercially available valves were used and the choice was left at the discretion of the medico-surgical team. Six centres implanted both devices. All operators received preliminary training (organized by the two companies) and were supervised on site for the first procedures (2 -6 for the Edwards; 10 -15 for the CoreValve). Inclusion criteria were: aortic valve area (AVA) ≤1 cm 2 or 0.6 cm 2 /m 2 ; severe symptoms (NYHA functional class II or more); logistic EuroSCORE ≥20% and/or STS risk score ≥10% and/or contraindication to AVR (porcelain aorta, chest deformation, chest radiation). Native aortic annulus diameter had to be measured 18 -24 mm for the Edwards SAPIEN and 20-27 mm for the CoreValve. Major exclusion criteria were: life expectancy ,12 months due to comorbid conditions; pre-existing aortic bioprosthesis; myocardial infarction ,14 days; unprotected .70% left main coronary artery disease; haemodynamic instability or cardiogenic shock; history of, or active, endocarditis; active peptic ulcer or upper gastro-intestinal bleeding within the prior 6 months; active infections requiring current antibiotic therapy or clinical suspicion of active infection; hypersensitivity or contraindication to aspirin, heparin, ticlopidine, or clopidogrel, or sensitivity to contrast media. All patients gave written informed consent.
Aim of the study
The purpose of this multicentre study is to evaluate the feasibility, safety, and efficacy of TAVI using the two available devices. The primary endpoint is mortality rate at 1 month, 6 months, 1, 2, and 3 years. The secondary endpoints are: (i) safety (major adverse cardiovascular and cerebrovascular events): myocardial infarction, cardiac or vascular surgery, and stroke, during the follow-up period; (ii) Efficacy with periodic assessment of aortic valve function by echocardiography: transvalvular mean pressure gradient, effective AVA, presence and severity of aortic valvular regurgitation, and/or mitral valve regurgitation. Further assessment includes: device success defined as successful delivery and deployment of the heart valve; NYHA heart failure functional class; quality of life and economic costs associated with cardiovascular resource utilization for the index hospitalization. In the present report, early and 30-day results are presented.
Device description
The design and the procedural characteristics of the two models have been described previously. 11 -13 
Procedure and adjunctive medication
Patients were assessed with transthoracic echocardiography (TTE) and if necessary transoesophageal echocardiography (TEE), selective coronary angiography, angiography of the aortic root and the aortoiliofemoral system, and CT scan of the aortoiliofemoral vessels + the entire aorta. Transfemoral and TA procedures were performed as previously described. 11 -13 There was no pre-specified recommendation for the choice of the TF or TA approach. Transarterial access was performed either percutaneously or after surgical cut-down, whereas TA access was obtained by anterior minithoracotomy. Implantation of the valve was preceded by balloon dilatation of the native aortic valve. Burst rapid pacing was used to reduce cardiac output during Edwards SAPIEN prosthesis deployment. The femoral access was closed either surgically or percutaneously (Prostar XL; Abbott, Inc., Chicago, IL, USA). All subjects received aspirin (at least 160 mg daily) and clopidogrel (300 mg loading dose, and then 75 mg daily) prior to procedure and for at least 1 month. Decision of general or local anaesthesia for TF implantation was left at the discretion of each team.
Data collection and quality control
Data were recorded using a standardized electronic case report form and sent to the central database (AXONAL, Nanterre, France) via Internet. Quality control was performed on all patients of randomly selected centres. Source document verification vs. data collected in the central database was performed on selected essential data.
Missing and/or inconsistent data were completed on site.
Statistical analysis
The results are expressed as the mean + SD, unless otherwise stated.
Comparison between groups and univariable analysis of the variables associated with 30-day mortality was performed using Student's t-test, ANOVA or non-parametric tests for continuous variables, and the x 2 test or Fisher's exact test where applicable for categorical variables. Variables with a P-value of ,0.20 in the univariable analysis were included in a multiple logistic model and selected backward with a P-value of 0.05. All statistical tests were two-sided. Statistical significance was accepted at P , 0.05. All data were analysed using SAS software (v8.2).
Results
The results are presented for the whole population and according to the approach and valve used.
Baseline characteristics
Transcatheter aortic valve implantation was attempted in a total of 244 patients. 
Procedural results
Data were available for 100% of patients. Device success (defined as stable device placement and adequate function in the first attempt as assessed by angiography + echocardiography) was 98.3% (240 of 244) ( Table 2) . Reasons of failure were: technical failure (one patient), too low valve position (one patient) leading to additional valve in valve implantation, and device migration in the ascending aorta (two patients) leading to death in one. Acute procedural success (defined as device success with the absence of periprocedural major cardiovascular events including death, tamponade, coronary artery occlusion in the first 24 h after device implantation) was 92.6% (226 of 244). Edwards SAPIEN bioprosthesis was implanted in 166 (68%) patients using the TF (n ¼ 95, 57%, including one retroperitoneal case) or the TA (n ¼ 71, 43%) approach, whereas the CoreValve was implanted in 78 (32%) patients using the TF (n ¼ 66, 84%) or the SC (n ¼ 12, 5%) approach. The vast majority of the procedures was performed under general anaesthesia (83.1%) in the cath lab (66.8%) with TEE guidance (74.1%). Transcatheter aortic valve implantation and grade IV in only one patient (0.5%). For the TF approach, percutaneous arterial closure was used in 26% of cases, more frequently after CoreValve implantation.
Early results
Complications and 1-month outcome
Data on mortality and complications were available for 100% of patients at 1 month. The complications are detailed in Table 3 . One-month mortality rate was 12.7% (31 patients). In multivariate analysis, success rate (odds ratio 0.024; 95% CI: 0.002 -0.278) and prior coronary artery bypass grafting (odds ratio, 0.156; 95% CI: 0.032 -0.766) were the only two factors significantly associated with a better survival at 1 month. Of note, 81% of deaths occurred within the first week, from cardio-vascular in the majority of them (two out of three). Three patients had acute per-procedural coronary occlusion. Arterial iliofemoral vessel dissection or rupture occurred in eight patients requiring balloon angioplasty in two, stenting in two, and vascular surgery in one. Rupture of the thoracic descending aorta in one led to immediate death. foot amputation), and surgical reintervention in one for persistent apical bleeding. Five patients (2%) experienced tamponade. Aortic annulus rupture in one and left ventricular perforation in one were documented, leading to death in both cases. Stroke occurred in nine patients (3.6%), haemorrhagic in one. A pacemaker was implanted in 29 patients (11.8%), more frequently after CoreValve implantation (P , 0.001). First-degree atrioventricular block was present in 2 of the 29 patients (6.9%) needing a pacemaker vs. 20 of the 215 patients (9.3%) who did not need a pacemaker (P ¼ 0.67). Left bundle branch block was present in 4 of the 29 patients (13.8%) needing a pacemaker vs. 23 of the 215 patients (10.7%) who did not need a pacemaker (P ¼ 0.62). Marked improvement of symptoms was observed in the vast majority of patients, 87.7% of them being in NYHA functional class II or less at 1 month (P , 0.001 vs. baseline). At 1 month, mean aortic gradient remained low (10.05 + 4.16 mmHg) and unchanged compared with post-implantation measurement, ejection fraction increased from 50.8 + 13.9% to 55.1 + 12.9%, P , 0.0001, and pulmonary systolic pressure decreased from 47 + 16 to 41.1 + 13.6 mmHg, P , 0.0004. Serum creatinine level which increased from 124.4 + 72.1 to 150 + 105 mmol/l after implantation was 123.1 + 71.1 mmol/l at 1 month. Haemoglobin which dropped from 12.1 + 1.8 to 9.9 + 4.4 g/l after implantation increased to 11.3 + 1.6 g/l at 1 month.
Discussion
This study reports the early results of the French multicentre experience using the two commercially available transcatheter heart valves. To our knowledge, our prospective registry is the first to report the combined experience on the two available valves using either the TF, TA, or SC approach.
Feasibility and efficacy
The device success rate is very high and consistent with previous single-centre reports. It appears that with careful screening, current techniques, proper training, and proctoring, short-term procedural success can be achieved in most patients. Efficacy has been already clearly demonstrated on early and mid-term outcomes with both devices. 14 -18 Final post-implantation mean transvalvular gradient is consistently low, 10 mmHg in average. Our immediate and 1-month results on valve function are as expected consistent with previous published data. The excellent haemodynamic results observed in our series resulted in improved left ventricular function as already reported 17 with remarkable clinical improvement. The rate of procedures performed under local anaesthesia without TEE guidance was quite low. It is likely that this rate will increase with growing experience and technical improvements in the devices such as reduction in introducer size.
Safety and early complications
In this elderly population of very sick patients, a 30-day mortality of 12.7% compares favourably with standard estimates of mortality. who used the TF approach in similar proportion (two-third). In Webb et al.'s series, major vascular injury rate was 8% using the TF approach and 3.6% using the TA approach and the rate was shown to decrease with experience. Similarly, Himbert et al.
15
reported a rate of 11% in their series including both TF and TA approaches. Worsening of renal function as assessed by creatinine elevation was noted in our series leading to acute renal failure requiring temporary dialysis in 1.6% of patients. In the vast majority of case, serum creatinine level returned to baseline value at 1 month.
Procedure type
The TF approach was used in 66% of procedures. The TA approach (Edwards SAPIEN) or SC approach (CoreValve) was most often selected as an alternative to the TF approach in case of inadequate peripheral vascular access. In the few centres implanting the two valves, because of the smaller introducer size, TF CoreValve could be preferred to TA Edwards SAPIEN when the femoral artery diameter was between 6 and 7 mm. As similarly reported, 10, 14, 15 patients treated by TA had more comorbidities than patients selected for TF, in particular more peripheral vascular disease which is known to increase the mortality risk. In our series, the EuroSCORE did not exceed 27% which may reflect the better 1-month survival in the TA group when compared with PARTNER EU trial (35%), presented by Schaechinger at EuroPCR meeting (Barcelona 2009) or Webb's cohort (33.8%). 14 The results driven from that prior studies with higher risk population and higher mortality rate may have led to more restrictive use of the TA approach in France in less-risk patients.
Valve type
Clearly, the CoreValve has today the advantage of a smaller introducer size (18 Fr) for TF access in comparison with the 22/24 French size necessary for Edwards SAPIEN valve implantation. This size allows for a larger use of TF implantation in smaller arteries (6.0 mm). As the TA approach is an alternative to TF for the Edwards SAPIEN device, the SC approach with the CoreValve is an alternative in patients with peripheral vascular disease. However, the current data remain limited 16, 19 and further evaluation is obviously needed. The only statistical difference between the two models of prosthesis is the higher rate of pacemaker implantation after CoreValve in comparison with Edwards SAPIEN. This has been consistently reported 16,20 -22 and well documented by Piazza et al. 23 and may result from a deeper intraventricular insertion of the self-expanding CoreValve beyond the non-coronary cusp. Large-scale long-term follow-up is still unavailable and will require further assessment. Webb et al.
14 demonstrated no valve dysfunction in 168 patients followed for up to 3 years. However, long-term durability of these prostheses must be proved prior to considering the expansion of the current indications to patients at a lower risk for AVR. Our registry is aimed to achieve a 3-year follow-up in all patients.
Study limitations
The study has the limitation of a registry, with no adjudication of patient inclusion, data collection, and analysis. The uniform assessment of selection strategy is questionable. More particularly, the rate of similarly ill patients not selected for TAVI but operated on or treated medically over the study period is not available. Finally, it is a non-randomized study which does not allow one to draw any formal conclusions on the risk/benefit of each prosthesis and approaches used.
Conclusion
Transcatheter aortic valve implantation allows patients who are at very high-surgical risk or with contraindications to surgical AVR to benefit from an effective treatment of severe AS. The availability of both transarterial and TA approaches and two devices increases the number of patients who can be treated. Our early results are satisfactory in terms of feasibility as well as short-term haemodynamic and functional improvement and safety given the high-risk patients' profile. Longer follow-up is mandatory to assess longterm durability and subsequently better define the indications and the respective places of devices and approaches.
